Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Jason Coloma, Ph.D., chief executive officer, will present a company overview and recent business highlights at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 3:00 p.m. PT in San Francisco.
A copy of the company’s presentation will be made available on MazeTx.com following the event.
About Maze Therapeutics
Maze Therapeutics is a biopharmaceutical company harnessing the power of human genetics to transform the lives of patients. The Company is committed to developing breakthrough precision medicines for common diseases with large unmet medical needs. Maze has developed Maze Compass™, a proprietary, purpose-built platform to leverage insights from genetic variation and integrate the critical step of variant functionalization into each stage of therapeutic development. Utilizing Maze Compass, the Company’s strategy is to develop its therapies independently, in collaboration with major pharmaceutical companies, and through company formation. For more information, please visit mazetx.com, or follow us on LinkedIn and X (formerly Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240103872274/en/
Contacts
Jillian Connell, Maze Therapeutics
jconnell@mazetx.com
(650) 850-5080
Media:
Dan Budwick, 1AB
dan@1abmedia.com
